GeneDx (NASDAQ:WGS) Trading 5.1% Higher – What’s Next?

Posted by Francis Steltz on Jun 23rd, 2026

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report)’s share price shot up 5.1% during trading on Tuesday . The stock traded as high as $57.76 and last traded at $58.2640. 56,346 shares traded hands during trading, a decline of 95% from the average daily volume of 1,036,675 shares. The stock had previously closed at $55.42.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Wall Street Zen lowered GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. BTIG Research dropped their price objective on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 24th. Wells Fargo & Company reissued an “overweight” rating and issued a $75.00 target price (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Jefferies Financial Group set a $150.00 target price on GeneDx in a report on Monday, February 23rd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $86.86.

Get Our Latest Research Report on GeneDx

GeneDx Trading Up 7.9%

The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $1.77 billion, a P/E ratio of -22.23 and a beta of 1.96. The company has a fifty day simple moving average of $54.16 and a two-hundred day simple moving average of $85.20.

GeneDx (NASDAQ:WGS – Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The business had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. During the same quarter last year, the company earned ($0.23) earnings per share. On average, sell-side analysts expect that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Kevin Feeley sold 3,729 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total value of $226,611.33. Following the completion of the transaction, the chief financial officer owned 39,954 shares in the company, valued at $2,428,004.58. This represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Casdin Capital, Llc acquired 50,000 shares of the stock in a transaction dated Friday, June 5th. The shares were bought at an average cost of $52.86 per share, with a total value of $2,643,000.00. Following the transaction, the director directly owned 3,707,164 shares of the company’s stock, valued at $195,960,689.04. This represents a 1.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 2,256,420 shares of company stock valued at $93,144,340 and sold 68,632 shares valued at $4,260,404. 25.17% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On GeneDx

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp raised its stake in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares during the period. Kestra Advisory Services LLC acquired a new position in shares of GeneDx during the fourth quarter worth about $27,000. Fifth Third Bancorp acquired a new position in shares of GeneDx during the first quarter worth about $31,000. Quarry LP grew its holdings in shares of GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares in the last quarter. Finally, Ramirez Asset Management Inc. bought a new position in shares of GeneDx during the fourth quarter worth about $33,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About GeneDx

(Get Free Report)

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.